MORF Morphic Holdings

Morphic to Participate in Jefferies IBD Therapeutics Summit

Morphic to Participate in Jefferies IBD Therapeutics Summit

WALTHAM, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of the Morphic leadership team are scheduled to take part in a fireside chat at the Jefferies Virtual Next Generation IBD Therapeutics Summit on October 19, 2021 at 3:15 p.m. ET.

A live webcast of the Jefferies fireside chat will be available on the Investor section of Morphic’s website at . An archived replay will be available on the company’s website following the conference.

About Morphic Therapeutic

Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit .

Contacts

Morphic Therapeutic

Chris Erdman



617.686.1718

Media Contact

Tom Donovan, Ten Bridge Communications



857.559.3397



EN
12/10/2021

Underlying

MORFMorphic Holdings

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Morphic Holdings

 PRESS RELEASE
Free
MORF Morphic Holding...

Morphic to Participate in Jefferies Global Healthcare Conference

Morphic to Participate in Jefferies Global Healthcare Conference WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will take part in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5th, at 10:30 AM ET. A live webcast of the panel discussion and fireside chat at the Jefferies Global Healthcare Conference will be available on the Investor section of Morphic’s we...

May 31, 2024 1 EN
 PRESS RELEASE
Free
MORF Morphic Holding...

Morphic Demonstrates Novel Real-Time Visualization of Small Molecule α...

Morphic Demonstrates Novel Real-Time Visualization of Small Molecule α4β7 Inhibition of Gut-Trafficking Cells -α4β7 Inhibition Rapidly Increases the Rolling Velocity and Flux of B Cells in Gut-associated Lymphoid Tissues- -Impact of Potent and Selective Small Molecule Inhibitor Comparable to Monoclonal Antibody Activity- -Preclinical Findings Presented at Digestive Disease Week 2024- WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced the...

May 21, 2024 1 EN
 PRESS RELEASE
Free
MORF Morphic Holding...

Morphic to Participate in RBC Capital Markets Global Healthcare Confer...

Morphic to Participate in RBC Capital Markets Global Healthcare Conference WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Marc Schegerin, COO and CFO, will take part in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at 9:00 AM ET. A live webcast of the panel discussion and fireside chat at the RBC Global Healthcare Conference will be available on the Investor section ...

May 9, 2024 1 EN
 PRESS RELEASE
Free
MORF Morphic Holding...

Morphic Announces Corporate Highlights and Financial Results for the F...

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024 - Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 in patients with moderate-to-severe Crohn’s disease in second quarter- -Ended first quarter with $658.8 million in cash, cash equivalents, and marketable securities; cash runway into second half of 2027- WALTHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- (Na...

April 25, 2024 1 EN
 PRESS RELEASE
Free
MORF Morphic Holding...

Morphic Appoints Dr. Simon Cooper as Chief Medical Officer

Morphic Appoints Dr. Simon Cooper as Chief Medical Officer Experienced Clinical Development Leader with Deep Experience in Immunology and Inflammatory Diseases WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer. Dr. Cooper is an accomplished leader in drug development with appreciable success and a proven history across all phases of clinical developm...

March 19, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch